Because few studies have been conducted on YKL-40 as a novel marker for predicting occult CAD in asymptomatic subjects with normal glucose tolerance or diabetes mellitus, our results make a novel contribution to the clinical relevance of YKL-40 in asymptomatic type 2 diabetic patients. This evidence concerns the gene CHI3L1 and type 2 diabetes mellitus.